M. Sherman, Hepatocellular Carcinoma: Epidemiology, Surveillance, and Diagnosis, Seminars in Liver Disease, vol.30, issue.01, pp.3-16, 2010.
DOI : 10.1055/s-0030-1247128

J. Ferlay, H. Shin, F. Bray, D. Forman, C. Mathers et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, International Journal of Cancer, vol.8, issue.19, pp.2893-2917, 2008.
DOI : 10.1002/ijc.25516

D. Parkin, F. Bray, J. Ferlay, and P. Pisani, Estimating the world cancer burden: Globocan 2000, International Journal of Cancer, vol.85, issue.2, pp.153-156, 2000.
DOI : 10.2105/AJPH.85.10.1356

URL : http://onlinelibrary.wiley.com/doi/10.1002/ijc.1440/pdf

A. Jemal, F. Bray, M. Center, J. Ferlay, E. Ward et al., Global cancer statistics, CA: A Cancer Journal for Clinicians, vol.82, issue.19 suppl, pp.69-90, 2011.
DOI : 10.1097/00002030-199912240-00012

H. El-serag, Hepatocellular Carcinoma, New England Journal of Medicine, vol.365, issue.12, pp.1118-1127, 2011.
DOI : 10.1056/NEJMra1001683

A. Belot, P. Grosclaude, N. Bossard, E. Jougla, E. Benhamou et al., Cancer incidence and mortality in France over the period 1980???2005, Revue d'??pid??miologie et de Sant?? Publique, vol.56, issue.3, pp.159-175, 2008.
DOI : 10.1016/j.respe.2008.03.117

URL : https://hal.archives-ouvertes.fr/inserm-00338335

F. Borie, B. Trétarre, A. Bouvier, J. Faivre, F. Binder et al., Primitive liver cancers: epidemiology and geographical study in France, European Journal of Gastroenterology & Hepatology, vol.21, issue.9, pp.984-989, 2009.
DOI : 10.1097/MEG.0b013e3283293783

R. Beasley, L. Hwang, C. Lin, and C. Chien, Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan, Lancet, vol.2, pp.1129-1133, 1981.

C. Chen, H. Yang, J. Su, C. Jen, S. You et al., Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level, JAMA, vol.295, issue.1, pp.65-73, 2006.
DOI : 10.1001/jama.295.1.65

M. Chang, C. Chen, M. Lai, H. Hsu, T. Wu et al., Universal Hepatitis B Vaccination in Taiwan and the Incidence of Hepatocellular Carcinoma in Children, New England Journal of Medicine, vol.336, issue.26, pp.1855-1859, 1997.
DOI : 10.1056/NEJM199706263362602

G. Fattovich, T. Stroffolini, I. Zagni, and F. Donato, Hepatocellular carcinoma in cirrhosis: Incidence and risk factors, Gastroenterology, vol.127, issue.5, pp.35-50, 2004.
DOI : 10.1053/j.gastro.2004.09.014

F. Donato, A. Tagger, U. Gelatti, G. Parrinello, P. Boffetta et al., Alcohol and Hepatocellular Carcinoma: The Effect of Lifetime Intake and Hepatitis Virus Infections in Men and Women, American Journal of Epidemiology, vol.155, issue.4, pp.323-331, 2002.
DOI : 10.1093/aje/155.4.323

R. Befrits, M. Hedman, L. Blomquist, T. Allander, L. Grillner et al., Chronic Hepatitis C in Alcoholic Patients: Prevalence, Genotypes, and Correlation to Liver Disease, Scandinavian Journal of Gastroenterology, vol.16, issue.11, pp.1113-1118, 1995.
DOI : 10.1002/hep.1840160203

P. Angulo and K. Lindor, Non-alcoholic fatty liver disease, Journal of Gastroenterology and Hepatology, vol.7, pp.186-190, 2002.
DOI : 10.1053/jlts.2001.23011

M. Ascha, I. Hanouneh, R. Lopez, T. Tamimi, A. Feldstein et al., The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis, Hepatology, vol.155, issue.Suppl. 1, pp.1972-1978, 2010.
DOI : 10.1093/aje/155.4.323

T. Ichikawa, K. Yanagi, Y. Motoyoshi, K. Hamasaki, K. Nakao et al., Two cases of non-alcoholic steatohepatitis with development of hepatocellular carcinoma without cirrhosis, Journal of Gastroenterology and Hepatology, vol.12, issue.12, pp.1865-1866, 2006.
DOI : 10.1007/s00535-003-1308-3

M. Sherman and J. Llovet, Smoking, Hepatitis B Virus Infection, and Development of Hepatocellular Carcinoma, JNCI Journal of the National Cancer Institute, vol.87, issue.9, pp.1642-1643, 2011.
DOI : 10.1038/sj.bjc.6600582

F. Bravi, C. Bosetti, A. Tavani, and C. Vecchia, Coffee drinking and hepatocellular carcinoma: An update, Hepatology, vol.48, issue.4, pp.1317-1318, 2009.
DOI : 10.1002/hep.23272

URL : http://onlinelibrary.wiley.com/doi/10.1002/hep.23272/pdf

Z. Zhang, Z. Zheng, R. Shi, Q. Su, Q. Jiang et al., Metformin for Liver Cancer Prevention in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis, The Journal of Clinical Endocrinology & Metabolism, vol.97, issue.7, pp.2347-2353, 2012.
DOI : 10.1210/jc.2012-1267

L. Fartoux, A. Poujol-robert, J. Guéchot, D. Wendum, R. Poupon et al., Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C, Gut, vol.54, issue.7, pp.1003-1008, 2005.
DOI : 10.1136/gut.2004.050302

H. Chiu, S. Ho, C. Chen, and C. Yang, Statin Use and the Risk of Liver Cancer: A Population-Based Case???Control Study, The American Journal of Gastroenterology, vol.100, issue.5, pp.894-898, 2011.
DOI : 10.1073/pnas.2237238100

Y. Tsan, C. Lee, J. Wang, and P. Chen, Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus Infection, Journal of Clinical Oncology, vol.30, issue.6, pp.623-630, 2012.
DOI : 10.1200/JCO.2011.36.0917

Y. Tsan, C. Lee, W. Ho, M. Lin, J. Wang et al., Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection, Journal of Clinical Oncology, vol.31, issue.12, pp.1514-1521, 2013.
DOI : 10.1200/JCO.2012.44.6831

A. Forner, J. Llovet, J. Bruix, and . Hepatocellular-carcinoma, Hepatocellular carcinoma, The Lancet, vol.379, issue.9822, pp.1245-1255, 2012.
DOI : 10.1016/S0140-6736(11)61347-0

URL : https://hal.archives-ouvertes.fr/hal-01134844

I. Levy, P. Greig, S. Gallinger, B. Langer, and M. Sherman, Resection of Hepatocellular Carcinoma Without Preoperative Tumor Biopsy, Annals of Surgery, vol.234, issue.2, pp.206-209, 2001.
DOI : 10.1097/00000658-200108000-00010

N. Snowberger, S. Chinnakotla, R. Lepe, J. Peattie, R. Goldstein et al., Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis, Alimentary Pharmacology & Therapeutics, vol.3, issue.9, pp.1187-1194, 2007.
DOI : 10.1016/0016-5085(85)90324-5

H. Xu, G. Liu, M. Lu, X. Xie, Z. Xu et al., Characterization of focal liver lesions using contrast-enhanced sonography with a low mechanical index mode and a sulfur hexafluoride-filled microbubble contrast agent, Journal of Clinical Ultrasound, vol.41, issue.6, pp.261-272, 2006.
DOI : 10.1148/radiology.208.2.9680590

J. Llovet, Y. Chen, E. Wurmbach, S. Roayaie, M. Fiel et al., A Molecular Signature to Discriminate Dysplastic Nodules From Early Hepatocellular Carcinoma in HCV Cirrhosis, Gastroenterology, vol.131, issue.6, pp.1758-1767, 2006.
DOI : 10.1053/j.gastro.2006.09.014

R. Stigliano, L. Marelli, D. Yu, N. Davies, D. Patch et al., Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome?, Cancer Treatment Reviews, vol.33, issue.5, pp.437-447, 2007.
DOI : 10.1016/j.ctrv.2007.04.001

G. Papatheodoridis, P. Lampertico, S. Manolakopoulos, and A. Lok, Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review, Journal of Hepatology, vol.53, issue.2, pp.348-356, 2010.
DOI : 10.1016/j.jhep.2010.02.035

A. Singal, A. Singh, S. Jaganmohan, P. Guturu, R. Mummadi et al., Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus???Related Cirrhosis, Clinical Gastroenterology and Hepatology, vol.8, issue.2, pp.192-199, 2010.
DOI : 10.1016/j.cgh.2009.10.026

S. Bruno, T. Stroffolini, M. Colombo, S. Bollani, L. Benvegnù et al., Sustained virological response to interferon-?? is associated with improved outcome in HCV-related cirrhosis: A retrospective study, Hepatology, vol.130, issue.3, pp.579-587, 2007.
DOI : 10.7326/0003-4819-116-2-97

D. Bisceglie, A. Shiffman, M. Everson, G. Lindsay, K. Everhart et al., Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon, New England Journal of Medicine, vol.359, issue.23, pp.2429-2441, 2008.
DOI : 10.1056/NEJMoa0707615

B. Zhang and Y. B. , Combined ?? fetoprotein testing and ultrasonography as a screening test for primary liver cancer, Journal of Medical Screening, vol.6, issue.2, pp.108-110, 1999.
DOI : 10.1136/jms.6.2.108

URL : http://journals.sagepub.com/doi/pdf/10.1136/jms.6.2.108

J. Llovet, C. Brú, and J. Bruix, Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification, Seminars in Liver Disease, vol.19, issue.03, pp.329-338, 1999.
DOI : 10.1055/s-2007-1007122

A. Kaseb, J. Abbruzzese, J. Vauthey, T. Aloia, E. Abdalla et al., I-CLIP: Improved Stratification of Advanced Hepatocellular Carcinoma Patients by Integrating Plasma IGF-1 into CLIP Score, Oncology, vol.91, issue.5-6, pp.373-381, 2011.
DOI : 10.1093/jnci/91.2.151

A. Kaseb, M. Hassan, E. Lin, L. Xiao, V. Kumar et al., V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials, Cancer, vol.247, issue.11, 2010.
DOI : 10.1001/jama.247.18.2543

S. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. Mcnabola et al., BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis, Cancer Research, vol.64, issue.19, pp.7099-7109, 2004.
DOI : 10.1158/0008-5472.CAN-04-1443

L. Liu, Y. Cao, C. Chen, X. Zhang, A. Mcnabola et al., Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5, Cancer Research, vol.66, issue.24, pp.11851-11858, 2006.
DOI : 10.1158/0008-5472.CAN-06-1377

H. Huynh, Molecularly targeted therapy in hepatocellular carcinoma, Biochemical Pharmacology, vol.80, issue.5, pp.550-560, 2010.
DOI : 10.1016/j.bcp.2010.03.034

A. Gauthier and M. Ho, Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update, Hepatology Research, vol.47, issue.suppl 4, pp.147-154, 2013.
DOI : 10.1016/j.ejca.2011.05.007

J. Dekervel, J. Van-pelt, and C. Verslype, Advanced unresectable hepatocellular carcinoma, Current Opinion in Oncology, vol.25, issue.4, pp.409-416, 2013.
DOI : 10.1097/CCO.0b013e3283621074

V. Boige, J. Barbare, and O. Rosmorduc, Utilisation du soraf??nib (Nexavar??) dans le traitement du carcinome h??patocellulaire??: recommandations Prodige Afef, Gastroent??rologie Clinique et Biologique, vol.32, issue.1, pp.3-7, 2008.
DOI : 10.1016/j.gcb.2007.11.001

B. Blanchet, B. Billemont, S. Barete, H. Garrigue, L. Cabanes et al., Toxicity of sorafenib: clinical and molecular aspects, Expert Opinion on Drug Safety, vol.3, issue.2, pp.275-287, 2010.
DOI : 10.1158/1078-0432.CCR-06-0051

J. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane et al., Sorafenib in Advanced Hepatocellular Carcinoma, New England Journal of Medicine, vol.359, issue.4, pp.378-390, 2008.
DOI : 10.1056/NEJMoa0708857

A. Cheng, Y. Kang, Z. Chen, C. Tsao, S. Qin et al., Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, The Lancet Oncology, vol.10, issue.1, pp.25-34, 2009.
DOI : 10.1016/S1470-2045(08)70285-7

M. Pinter, W. Sieghart, F. Hucke, I. Graziadei, W. Vogel et al., Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib, Alimentary Pharmacology & Therapeutics, vol.127, issue.8, pp.949-959, 2011.
DOI : 10.1053/j.gastro.2004.09.015

G. Abou-alfa, D. Amadori, A. Santoro, A. Figer, D. Greve et al., Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis, Gastrointest Cancer Res, vol.4, pp.40-44, 2011.

A. Hollebecque, S. Cattan, O. Romano, G. Sergent, A. Mourad et al., Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score, Alimentary Pharmacology & Therapeutics, vol.30, issue.10, pp.1193-1201, 2011.
DOI : 10.1055/s-0030-1247131

D. Costanzo, G. Tortora, R. Iodice, L. Lanza, A. Lampasi et al., Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice, Digestive and Liver Disease, vol.44, issue.9, pp.788-792, 2012.
DOI : 10.1016/j.dld.2012.04.001

R. Lencioni and J. Llovet, Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma, Seminars in Liver Disease, vol.30, issue.01, pp.52-60, 2010.
DOI : 10.1055/s-0030-1247132

URL : http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0030-1247132.pdf

A. Waghray, B. Balci, G. El-gazzaz, R. Kim, R. Pelley et al., Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation, Clinical Transplantation, vol.16, issue.4, 2013.
DOI : 10.1002/lt.22047

M. Wörns, A. Weinmann, K. Pfingst, C. Schulte-sasse, C. Messow et al., Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis, Journal of Clinical Gastroenterology, vol.43, issue.5, pp.489-495, 2009.
DOI : 10.1097/MCG.0b013e31818ddfc6

R. Lencioni, M. Kudo, S. Ye, J. Bronowicki, X. Chen et al., First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study, International Journal of Clinical Practice, vol.115, issue.Suppl 4, pp.675-683, 2012.
DOI : 10.1002/cncr.24029

D. Yoon, B. Ryoo, M. Ryu, S. Lee, S. Hwang et al., Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation, Japanese Journal of Clinical Oncology, vol.13, issue.3, pp.768-773, 2010.
DOI : 10.1002/lt.21043

J. Kim, B. Ryoo, M. Ryu, H. Chang, D. Suh et al., Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma, Oncology, vol.4, issue.2, pp.119-125, 2012.
DOI : 10.1002/hep.20933

M. Kudo, K. Imanaka, N. Chida, K. Nakachi, W. Tak et al., Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma, European Journal of Cancer, vol.47, issue.14, pp.2117-2127, 2011.
DOI : 10.1016/j.ejca.2011.05.007

Y. Chung, G. Han, J. Yoon, Y. J. Wang, J. Shao et al., Interim analysis of START: Study in asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial, International Journal of Cancer, vol.28, issue.10, pp.2448-2458, 2013.
DOI : 10.1200/jco.2010.28.15_suppl.tps178

T. Pawlik, D. Reyes, D. Cosgrove, I. Kamel, N. Bhagat et al., Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular Carcinoma, Journal of Clinical Oncology, vol.29, issue.30, pp.3960-3967, 2011.
DOI : 10.1200/JCO.2011.37.1021

R. Cabrera, D. Pannu, J. Caridi, R. Firpi, C. Soldevila-pico et al., The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma, Alimentary Pharmacology & Therapeutics, vol.23, issue.2, pp.205-213, 2011.
DOI : 10.1111/j.1365-2036.2006.02704.x

I. Petrini, M. Lencioni, M. Ricasoli, M. Iannopollo, C. Orlandini et al., Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma, Cancer Chemotherapy and Pharmacology, vol.7, issue.3, pp.773-780, 2012.
DOI : 10.1016/S1359-6349(09)72082-8

G. Abou-alfa, P. Johnson, J. Knox, M. Capanu, I. Davidenko et al., Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma, JAMA, vol.304, issue.19, pp.2154-2160, 2010.
DOI : 10.1001/jama.2010.1672

C. Hsu, Y. Shen, Z. Lin, P. Chen, Y. Shao et al., Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma, Journal of Hepatology, vol.53, issue.1, pp.126-131, 2010.
DOI : 10.1016/j.jhep.2010.01.035

D. Hicklin and L. Ellis, Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis, Journal of Clinical Oncology, vol.23, issue.5, pp.1011-1027, 2005.
DOI : 10.1200/JCO.2005.06.081

A. Kaipainen, J. Korhonen, T. Mustonen, V. Van-hinsbergh, G. Fang et al., Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development., Proceedings of the National Academy of Sciences, vol.92, issue.8, pp.3566-3570, 1995.
DOI : 10.1073/pnas.92.8.3566

L. Ellis, The role of neuropilins in cancer, Molecular Cancer Therapeutics, vol.5, issue.5, pp.1099-1107, 2006.
DOI : 10.1158/1535-7163.MCT-05-0538

L. Ellis and D. Hicklin, VEGF-targeted therapy: mechanisms of anti-tumour activity, Nature Reviews Cancer, vol.119, issue.8, pp.579-591, 2008.
DOI : 10.4161/cbt.6.8.4363

R. Kerbel, Tumor Angiogenesis, New England Journal of Medicine, vol.358, issue.19, pp.2039-2049, 2008.
DOI : 10.1056/NEJMra0706596

J. Lee, N. Chow, S. Wang, and S. Huang, Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients, European Journal of Cancer, vol.36, issue.6, pp.748-753, 2000.
DOI : 10.1016/S0959-8049(00)00003-4

Y. Takahashi, Y. Kitadai, C. Bucana, K. Cleary, and L. Ellis, Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer, Cancer Res, vol.55, pp.3964-3968, 1995.

Y. Takahashi, K. Cleary, M. Mai, Y. Kitadai, C. Bucana et al., Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer, Clin. Cancer Res, vol.2, pp.1679-1684, 1996.

K. Maeda, Y. Chung, Y. Ogawa, S. Takatsuka, S. Kang et al., Prognostic value of vascular endothelial growth factor expression in gastric carcinoma, Cancer, vol.948, issue.5, pp.858-863, 1996.
DOI : 10.1111/j.1349-7006.1994.tb02904.x

K. Fujimoto, R. Hosotani, M. Wada, J. Lee, T. Koshiba et al., Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis, European Journal of Cancer, vol.34, issue.9, pp.1439-1447, 1998.
DOI : 10.1016/S0959-8049(98)00069-0

N. Ikeda, M. Adachi, T. Taki, C. Huang, H. Hashida et al., Prognostic significance of angiogenesis in human pancreatic cancer, British Journal of Cancer, vol.79, issue.9-10, pp.1553-1563, 1999.
DOI : 10.1038/sj.bjc.6690248

D. George, S. Halabi, T. Shepard, N. Vogelzang, D. Hayes et al., Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480, Clin. Cancer Res, vol.7, pp.1932-1936, 2001.

E. Berns, J. Klijn, M. Look, N. Grebenchtchikov, R. Vossen et al., Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer, Clin. Cancer Res, vol.9, pp.1253-1258, 2003.

P. Manders, L. Beex, V. Tjan-heijnen, J. Geurts-moespot, T. Van-tienoven et al., The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy, British Journal of Cancer, vol.3, issue.7, pp.772-778, 2002.
DOI : 10.1007/BF00666040

G. Fontanini, M. Lucchi, S. Vignati, A. Mussi, F. Ciardiello et al., Angiogenesis as a Prognostic Indicator of Survival in Non-Small-Cell Lung Carcinoma: a Prospective Study, JNCI Journal of the National Cancer Institute, vol.348, issue.6301, pp.881-886, 1997.
DOI : 10.1038/348555a0

D. Gorski, A. Leal, and J. Goydos, Differential expression of vascular endothelial growth factor???A isoforms at different stages of melanoma progression, Journal of the American College of Surgeons, vol.197, issue.3, pp.408-418, 2003.
DOI : 10.1016/S1072-7515(03)00388-0

J. Guo, X. Zhu, X. Li, and R. Yang, Impact of serum vascular endothelial growth factor on prognosis in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization, Chinese Journal of Cancer Research, vol.24, issue.1, pp.36-43, 2012.
DOI : 10.1007/s11670-012-0036-8

G. Huang, L. Yang, and W. Lu, Expression of hypoxia-inducible factor 1?? and vascular endothelial growth factor in hepatocellular carcinoma: Impact on neovascularization and survival, World Journal of Gastroenterology, vol.11, issue.11, pp.1705-1708, 2005.
DOI : 10.1002/1097-0142(20010701)92:1<165::AID-CNCR1305>3.0.CO;2-F

Z. Xiang, Z. Zeng, F. J. Tang, Z. Zeng, H. Gao et al., Gene Expression Profiling of Fixed Tissues Identified Hypoxia-Inducible Factor-1??, VEGF, and Matrix Metalloproteinase-2 as Biomarkers of Lymph Node Metastasis in Hepatocellular Carcinoma, Clinical Cancer Research, vol.17, issue.16, pp.5463-5472, 2011.
DOI : 10.1158/1078-0432.CCR-10-3096

R. Poon, C. Lau, J. Ho, W. Yu, S. Fan et al., Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma, Clin. Cancer Res, vol.9, pp.5339-5345, 2003.

A. Sergio, C. Cristofori, R. Cardin, G. Pivetta, R. Ragazzi et al., Transcatheter Arterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): The Role of Angiogenesis and Invasiveness, The American Journal of Gastroenterology, vol.21, issue.4, pp.914-921, 2008.
DOI : 10.1016/0006-291X(91)91276-I

J. Llovet, C. Peña, C. Lathia, M. Shan, G. Meinhardt et al., Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma, Clinical Cancer Research, vol.18, issue.8, pp.2290-2300, 2012.
DOI : 10.1158/1078-0432.CCR-11-2175

A. Siegel, E. Cohen, A. Ocean, D. Lehrer, A. Goldenberg et al., Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma, Journal of Clinical Oncology, vol.26, issue.18, pp.2992-2998, 2008.
DOI : 10.1200/JCO.2007.15.9947

A. Zhu, L. Blaszkowsky, D. Ryan, J. Clark, A. Muzikansky et al., Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma, Journal of Clinical Oncology, vol.24, issue.12, pp.1898-1903, 2006.
DOI : 10.1200/JCO.2005.04.9130

M. Thomas, J. Morris, R. Chadha, M. Iwasaki, H. Kaur et al., Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma, Journal of Clinical Oncology, vol.27, issue.6, pp.843-850, 2009.
DOI : 10.1200/JCO.2008.18.3301

S. Chan and W. Yeo, Targeted therapy of hepatocellular carcinoma: Present and future, Journal of Gastroenterology and Hepatology, vol.47, issue.18S, pp.862-872, 2012.
DOI : 10.1016/j.ejca.2011.04.027

S. Faivre, R. E. Boucher, E. Douillard, J. Lim, H. Kim et al., Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study, The Lancet Oncology, vol.10, issue.8, pp.794-800, 2009.
DOI : 10.1016/S1470-2045(09)70171-8

A. Zhu, D. Sahani, D. Duda, E. Di-tomaso, M. Ancukiewicz et al., Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study, Journal of Clinical Oncology, vol.27, issue.18, pp.3027-3035, 2009.
DOI : 10.1200/JCO.2008.20.9908

R. Finn, Emerging Targeted Strategies in Advanced Hepatocellular Carcinoma, Seminars in Liver Disease, vol.33, issue.S 01, pp.11-19, 2013.
DOI : 10.1055/s-0033-1333632

URL : http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0033-1333632.pdf

J. Llovet, T. Decaens, R. J. Boucher, E. Kudo, M. Chang et al., Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study, Journal of Clinical Oncology, vol.31, issue.28, 2013.
DOI : 10.1200/JCO.2012.47.3009

L. Saltz, S. Clarke, E. Díaz-rubio, W. Scheithauer, A. Figer et al., Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study, Journal of Clinical Oncology, vol.26, issue.12, pp.2013-2019, 2008.
DOI : 10.1200/JCO.2007.14.9930

K. Chen, H. Chen, W. Tai, W. Feng, C. Hsu et al., Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells, Journal of Pharmacology and Experimental Therapeutics, vol.337, issue.1, pp.155-161, 2011.
DOI : 10.1124/jpet.110.175786

T. Batchelor, A. Sorensen, E. Di-tomaso, W. Zhang, D. Duda et al., AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients, Cancer Cell, vol.11, issue.1, pp.83-95, 2007.
DOI : 10.1016/j.ccr.2006.11.021

L. Ellis and D. Hicklin, Pathways Mediating Resistance to Vascular Endothelial Growth Factor-Targeted Therapy, Clinical Cancer Research, vol.14, issue.20, pp.6371-6375, 2008.
DOI : 10.1158/1078-0432.CCR-07-5287

URL : http://clincancerres.aacrjournals.org/content/clincanres/14/20/6371.full.pdf

G. Bergers and D. Hanahan, Modes of resistance to anti-angiogenic therapy, Nature Reviews Cancer, vol.25, issue.8, pp.592-603, 2008.
DOI : 10.1016/S0002-9440(10)64083-7

O. Casanovas, D. Hicklin, G. Bergers, and D. Hanahan, Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors, Cancer Cell, vol.8, issue.4, pp.299-309, 2005.
DOI : 10.1016/j.ccr.2005.09.005

M. Blivet-van-eggelpoël, H. Chettouh, L. Fartoux, L. Aoudjehane, V. Barbu et al., Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells, Journal of Hepatology, vol.57, issue.1, pp.108-115, 2012.
DOI : 10.1016/j.jhep.2012.02.019

K. Hirschi, D. Amore, and P. , Control of angiogenesis by the pericyte: Molecular mechanisms and significance, EXS, vol.79, pp.419-428, 1997.
DOI : 10.1007/978-3-0348-9006-9_18

T. Pressiani, C. Boni, L. Rimassa, R. Labianca, S. Fagiuoli et al., Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis, Annals of Oncology, vol.44, issue.1, 2012.
DOI : 10.1016/j.jhep.2005.10.013

P. Zuk, M. Zhu, P. Ashjian, D. Ugarte, D. Huang et al., Human Adipose Tissue Is a Source of Multipotent Stem Cells, Molecular Biology of the Cell, vol.13, issue.12, pp.4279-4295, 2002.
DOI : 10.1091/mbc.E02-02-0105

D. Crandall, G. Hausman, and J. Kral, A Review of the Microcirculation of Adipose Tissue: Anatomic, Metabolic, and Angiogenic Perspectives, Microcirculation, vol.4, issue.2, pp.211-232, 1997.
DOI : 10.3109/10739689709146786

E. Bråkenhielm, R. Cao, B. Gao, B. Angelin, B. Cannon et al., Angiogenesis Inhibitor, TNP-470, Prevents Diet-Induced and Genetic Obesity in Mice, Circulation Research, vol.94, issue.12, pp.1579-1588, 2004.
DOI : 10.1161/01.RES.0000132745.76882.70

M. Rupnick, D. Panigrahy, C. Zhang, S. Dallabrida, B. Lowell et al., Adipose tissue mass can be regulated through the vasculature, Proceedings of the National Academy of Sciences, vol.294, issue.5542, pp.10730-10735, 2002.
DOI : 10.1126/science.1063889

Y. Cao, Angiogenesis modulates adipogenesis and obesity, Journal of Clinical Investigation, vol.117, issue.9, pp.2362-2368, 2007.
DOI : 10.1172/JCI32239

URL : http://www.jci.org/articles/view/32239/files/pdf

J. Rehman, D. Traktuev, J. Li, S. Merfeld-clauss, C. Temm-grove et al., Secretion of Angiogenic and Antiapoptotic Factors by Human Adipose Stromal Cells, Circulation, vol.109, issue.10, pp.1292-1298, 2004.
DOI : 10.1161/01.CIR.0000121425.42966.F1

C. Cho, Y. Koh, J. Han, H. Sung, J. Lee et al., Angiogenic Role of LYVE-1-Positive Macrophages in Adipose Tissue, Circulation Research, vol.100, issue.4, pp.47-57, 2007.
DOI : 10.1161/01.RES.0000259564.92792.93

J. Silha, M. Krsek, P. Sucharda, and L. Murphy, Angiogenic factors are elevated in overweight and obese individuals, International Journal of Obesity, vol.27, issue.11, pp.1308-1314, 2005.
DOI : 10.1038/sj.ijo.0802408

J. Rehman, R. Considine, J. Bovenkerk, J. Li, C. Slavens et al., Obesity is associated with increased levels of circulating hepatocyte growth factor, Journal of the American College of Cardiology, vol.41, issue.8, pp.1408-1413, 2003.
DOI : 10.1016/S0735-1097(03)00231-6

E. Dusserre, P. Moulin, and H. Vidal, Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol.1500, issue.1, pp.88-96, 2000.
DOI : 10.1016/S0925-4439(99)00091-5

M. Shibasaki, K. Takahashi, T. Itou, S. Miyazawa, M. Ito et al., Alterations of insulin sensitivity by the implantation of 3T3-L1 cells in nude mice. A role for TNF-alpha? Diabetologia, pp.518-526, 2002.

S. Miyazawa-hoshimoto, K. Takahashi, H. Bujo, N. Hashimoto, and Y. Saito, Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects, Diabetologia, vol.46, issue.11, pp.1483-1488, 2003.
DOI : 10.1007/s00125-003-1221-6

J. Kuk, S. Lee, S. Heymsfield, and R. Ross, Waist circumference and abdominal adipose tissue distribution: influence of age and sex, The American Journal of Clinical Nutrition, vol.12, issue.6, pp.1330-1334, 2005.
DOI : 10.1038/oby.2004.60

H. Kvist, B. Chowdhury, L. Sjöström, U. Tylén, and A. Cederblad, Adipose tissue volume determination in males by computed tomography and 40K, Int J Obes, vol.12, pp.249-266, 1988.

A. Renehan, M. Tyson, M. Egger, R. Heller, and M. Zwahlen, Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies, The Lancet, vol.371, issue.9612, pp.569-578, 2008.
DOI : 10.1016/S0140-6736(08)60269-X

G. Reeves, K. Pirie, V. Beral, J. Green, E. Spencer et al., Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study, BMJ, vol.335, issue.7630, p.1134, 2007.
DOI : 10.1136/bmj.39367.495995.AE

E. Calle, C. Rodriguez, K. Walker-thurmond, and M. Thun, Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults, New England Journal of Medicine, vol.348, issue.17, pp.1625-1638, 2003.
DOI : 10.1056/NEJMoa021423

Y. Cui, M. Whiteman, P. Langenberg, M. Sexton, K. Tkaczuk et al., Can Obesity Explain the Racial Difference in Stage of Breast Cancer at Diagnosis between Black and White Women?, Journal of Women's Health & Gender-Based Medicine, vol.11, issue.6, pp.527-536, 2002.
DOI : 10.1089/152460902760277886

B. Maehle, S. Tretli, R. Skjaerven, and T. Thorsen, Premorbid body weight and its relations to primary tumour diameter in breast cancer patients; its dependence on estrogen and progesteron receptor status, Breast Cancer Research and Treatment, vol.123, issue.5, pp.159-169, 2001.
DOI : 10.1093/oxfordjournals.aje.a114305

S. Freedland, W. Aronson, C. Kane, J. Presti, . Jr et al., Impact of Obesity on Biochemical Control After Radical Prostatectomy for Clinically Localized Prostate Cancer: A Report by the Shared Equal Access Regional Cancer Hospital Database Study Group, Journal of Clinical Oncology, vol.22, issue.3, pp.446-453, 2004.
DOI : 10.1200/JCO.2004.04.181

J. Dignam, B. Polite, G. Yothers, P. Raich, L. Colangelo et al., Body Mass Index and Outcomes in Patients Who Receive Adjuvant Chemotherapy for Colon Cancer, JNCI: Journal of the National Cancer Institute, vol.98, issue.22, pp.1647-1654, 2006.
DOI : 10.1200/JCO.2006.06.0863

B. Guiu, J. Petit, F. Bonnetain, S. Ladoire, S. Guiu et al., Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer, Gut, vol.59, issue.3, pp.341-347, 2010.
DOI : 10.1136/gut.2009.188946

URL : https://hal.archives-ouvertes.fr/inserm-00476649

S. Steffens, V. Grünwald, K. Ringe, C. Seidel, H. Eggers et al., Does Obesity Influence the Prognosis of Metastatic Renal Cell Carcinoma in Patients Treated with Vascular Endothelial Growth Factor-Targeted Therapy?, The Oncologist, vol.16, issue.11, pp.1565-1571, 2011.
DOI : 10.1634/theoncologist.2011-0213

S. Ladoire, F. Bonnetain, M. Gauthier, S. Zanetta, J. Petit et al., Visceral Fat Area as a New Independent Predictive Factor of Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Antiangiogenic Agents, The Oncologist, vol.16, issue.1, pp.71-81, 2011.
DOI : 10.1634/theoncologist.2010-0227

G. Baffy, E. Brunt, and S. Caldwell, Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace, Journal of Hepatology, vol.56, issue.6, pp.1384-1391, 2012.
DOI : 10.1016/j.jhep.2011.10.027

D. Preiss and N. Sattar, Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations, Clinical Science, vol.115, issue.5, pp.141-150, 2008.
DOI : 10.1042/CS20070402

G. Ioannou, M. Splan, N. Weiss, G. Mcdonald, L. Beretta et al., Incidence and Predictors of Hepatocellular Carcinoma in Patients With Cirrhosis, Clinical Gastroenterology and Hepatology, vol.5, issue.8, pp.938-945, 2007.
DOI : 10.1016/j.cgh.2007.02.039

S. Nair, A. Mason, J. Eason, G. Loss, and R. Perrillo, Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?, Hepatology, vol.73, issue.1, pp.150-155, 2002.
DOI : 10.1002/1097-0142(19940101)73:1<42::AID-CNCR2820730109>3.0.CO;2-D

T. Ohki, R. Tateishi, T. Sato, R. Masuzaki, J. Imamura et al., Obesity Is an Independent Risk Factor for Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients, Clinical Gastroenterology and Hepatology, vol.6, issue.4, pp.459-464, 2008.
DOI : 10.1016/j.cgh.2008.02.012

L. Iacono, O. Venezia, G. Petta, S. Mineo, C. et al., The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C, Alimentary Pharmacology & Therapeutics, vol.55, issue.Suppl. 2, pp.1181-1191, 2007.
DOI : 10.7326/0003-4819-140-5-200403020-00010

J. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane et al., Sorafenib in Advanced Hepatocellular Carcinoma, New England Journal of Medicine, vol.359, issue.4, pp.378-390, 2008.
DOI : 10.1056/NEJMoa0708857

A. Cheng, Y. Kang, Z. Chen, C. Tsao, S. Qin et al., Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, The Lancet Oncology, vol.10, issue.1, pp.25-34, 2009.
DOI : 10.1016/S1470-2045(08)70285-7

M. Sherman, Hepatocellular Carcinoma: Epidemiology, Surveillance, and Diagnosis, Seminars in Liver Disease, vol.30, issue.01, pp.3-16, 2010.
DOI : 10.1055/s-0030-1247128

A. Villanueva, P. Newell, D. Chiang, S. Friedman, and J. Llovet, Genomics and Signaling Pathways in Hepatocellular Carcinoma, Seminars in Liver Disease, vol.27, issue.1, pp.55-76, 2007.
DOI : 10.1055/s-2006-960171

S. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. Mcnabola et al., BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis, Cancer Research, vol.64, issue.19, pp.7099-7109, 2004.
DOI : 10.1158/0008-5472.CAN-04-1443

J. Rehman, D. Traktuev, J. Li, S. Merfeld-clauss, C. Temm-grove et al., Secretion of Angiogenic and Antiapoptotic Factors by Human Adipose Stromal Cells, Circulation, vol.109, issue.10, pp.1292-1298, 2004.
DOI : 10.1161/01.CIR.0000121425.42966.F1

C. Cho, Y. Koh, J. Han, H. Sung, J. Lee et al., Angiogenic Role of LYVE-1-Positive Macrophages in Adipose Tissue, Circulation Research, vol.100, issue.4, pp.47-57, 2007.
DOI : 10.1161/01.RES.0000259564.92792.93

S. Miyazawa-hoshimoto, K. Takahashi, H. Bujo, N. Hashimoto, and Y. Saito, Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects, Diabetologia, vol.46, issue.11, pp.1483-1488, 2003.
DOI : 10.1007/s00125-003-1221-6

B. Guiu, J. Petit, F. Bonnetain, S. Ladoire, S. Guiu et al., Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer, Gut, vol.59, issue.3, pp.341-347, 2010.
DOI : 10.1136/gut.2009.188946

URL : https://hal.archives-ouvertes.fr/inserm-00476649

S. Ladoire, F. Bonnetain, M. Gauthier, S. Zanetta, J. Petit et al., Visceral Fat Area as a New Independent Predictive Factor of Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Antiangiogenic Agents, The Oncologist, vol.16, issue.1, pp.71-81, 2011.
DOI : 10.1634/theoncologist.2010-0227

J. Bruix and M. Sherman, Management of hepatocellular carcinoma, Hepatology, vol.35, issue.5, pp.1208-1236, 2005.
DOI : 10.1016/0016-5085(88)90436-2

J. Bruix and M. Sherman, Management of hepatocellular carcinoma: An update, Hepatology, vol.10, issue.Suppl 1, pp.1020-1022, 2011.
DOI : 10.1016/S1470-2045(08)70285-7

J. Llovet, D. Bisceglie, A. Bruix, J. Kramer, B. Lencioni et al., Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma, JNCI Journal of the National Cancer Institute, vol.12, issue.4, pp.698-711, 2008.
DOI : 10.1038/nm1377

R. Lencioni and J. Llovet, Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma, Seminars in Liver Disease, vol.30, issue.01, pp.52-60, 2010.
DOI : 10.1055/s-0030-1247132

URL : http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0030-1247132.pdf

T. Yoshizumi, T. Nakamura, M. Yamane, A. Islam, M. Menju et al., Abdominal Fat: Standardized Technique for Measurement at CT, Radiology, vol.211, issue.1, pp.283-286, 1999.
DOI : 10.1148/radiology.211.1.r99ap15283

E. Delong, D. Delong, and D. Clarke-pearson, Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach, Biometrics, vol.44, issue.3, pp.837-845, 1988.
DOI : 10.2307/2531595

M. Kudo, K. Ueshima, and T. Arizumi, Real-Life Clinical Practice with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Center Experience, Digestive Diseases, vol.1, issue.6, pp.609-616, 2012.
DOI : 10.1159/000339016

A. Hollebecque, S. Cattan, O. Romano, G. Sergent, A. Mourad et al., Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score, Alimentary Pharmacology & Therapeutics, vol.30, issue.10, pp.1193-1201, 2011.
DOI : 10.1055/s-0030-1247131

D. Costanzo, G. Tortora, R. Iodice, L. Lanza, A. Lampasi et al., Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice, Digestive and Liver Disease, vol.44, issue.9, pp.788-792, 2012.
DOI : 10.1016/j.dld.2012.04.001

T. Pressiani, C. Boni, L. Rimassa, R. Labianca, S. Fagiuoli et al., Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis, Annals of Oncology, vol.44, issue.1, 2012.
DOI : 10.1016/j.jhep.2005.10.013

M. Pinter, W. Sieghart, F. Hucke, I. Graziadei, W. Vogel et al., Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib, Alimentary Pharmacology & Therapeutics, vol.127, issue.8, pp.949-959, 2011.
DOI : 10.1053/j.gastro.2004.09.015

R. Koschny, D. Gotthardt, C. Koehler, D. Jaeger, W. Stremmel et al., Diarrhea Is a Positive Outcome Predictor for Sorafenib Treatment of Advanced Hepatocellular Carcinoma, Oncology, vol.84, issue.1, pp.6-13, 2013.
DOI : 10.1159/000342425

J. Bruix, R. J. Sherman, M. Mazzaferro, V. Bolondi, L. Craxi et al., Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial, Journal of Hepatology, vol.57, issue.4, pp.821-829, 2012.
DOI : 10.1016/j.jhep.2012.06.014

V. Boige, J. Barbare, and O. Rosmorduc, Utilisation du soraf??nib (Nexavar??) dans le traitement du carcinome h??patocellulaire??: recommandations Prodige Afef, Gastroent??rologie Clinique et Biologique, vol.32, issue.1, pp.3-7, 2008.
DOI : 10.1016/j.gcb.2007.11.001

G. Abou-alfa, D. Amadori, A. Santoro, A. Figer, D. Greve et al., Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis, Gastrointest Cancer Res, vol.4, pp.40-44, 2011.

R. Lencioni, M. Kudo, S. Ye, J. Bronowicki, X. Chen et al., First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study, International Journal of Clinical Practice, vol.115, issue.Suppl 4, pp.675-683, 2012.
DOI : 10.1002/cncr.24029

J. Kim, B. Ryoo, M. Ryu, H. Chang, D. Suh et al., Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function, Cancer Chemotherapy and Pharmacology, vol.135, issue.5, pp.1285-1290, 2011.
DOI : 10.1007/s00432-008-0496-x

Y. Cao, Angiogenesis modulates adipogenesis and obesity, Journal of Clinical Investigation, vol.117, issue.9, pp.2362-2368, 2007.
DOI : 10.1172/JCI32239

URL : http://www.jci.org/articles/view/32239/files/pdf

J. Silha, M. Krsek, P. Sucharda, and L. Murphy, Angiogenic factors are elevated in overweight and obese individuals, International Journal of Obesity, vol.27, issue.11, pp.1308-1314, 2005.
DOI : 10.1038/sj.ijo.0802408

E. Calle, C. Rodriguez, K. Walker-thurmond, and M. Thun, Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults, New England Journal of Medicine, vol.348, issue.17, pp.1625-1638, 2003.
DOI : 10.1056/NEJMoa021423

T. Ohki, R. Tateishi, S. Shiina, E. Goto, T. Sato et al., Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH, Gut, vol.58, issue.6, pp.839-844, 2009.
DOI : 10.1136/gut.2008.164053

K. Miyahara, K. Nouso, T. Tomoda, S. Kobayashi, H. Hagihara et al., Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma, Journal of Gastroenterology and Hepatology, vol.82, issue.1, pp.1604-1611, 2011.
DOI : 10.3109/17453674.2011.555368

J. Llovet, C. Peña, C. Lathia, M. Shan, G. Meinhardt et al., Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma, Clinical Cancer Research, vol.18, issue.8, pp.2290-2300, 2012.
DOI : 10.1158/1078-0432.CCR-11-2175

J. Kuk, S. Lee, S. Heymsfield, and R. Ross, Waist circumference and abdominal adipose tissue distribution: influence of age and sex, The American Journal of Clinical Nutrition, vol.12, issue.6, pp.1330-1334, 2005.
DOI : 10.1038/oby.2004.60

H. Kvist, B. Chowdhury, L. Sjöström, U. Tylén, and A. Cederblad, Adipose tissue volume determination in males by computed tomography and 40K, Int J Obes, vol.12, pp.249-266, 1988.

H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth et al., Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.350, issue.23, pp.2335-2342, 2004.
DOI : 10.1056/NEJMoa032691

F. Kabbinavar, C. Irl, A. Zurlo, and H. Hurwitz, Bevacizumab Improves the Overall and Progression-Free Survival of Patients with Metastatic Colorectal Cancer Treated with 5-Fluorouracil-Based Regimens Irrespective of Baseline Risk, Oncology, vol.75, issue.3-4, pp.215-223, 2008.
DOI : 10.1159/000163850

J. Bronowicki, S. Ye, M. Kudo, J. Marrero, L. Dagher et al., 109 GIDEON (GLOBAL INVESTIGATION OF THERAPEUTIC DECISIONS IN HEPATOCELLULAR CARCINOMA AND OF ITS TREATMENT WITH SORAFENIB) SECOND INTERIM ANALYSIS: CLINICAL FINDINGS IN CHILD-PUGH B SCORE SUBGROUPS, Journal of Hepatology, vol.56, pp.48-49, 2012.
DOI : 10.1016/S0168-8278(12)60123-8

J. Meza-junco, A. Montano-loza, V. Baracos, C. Prado, V. Bain et al., Sarcopenia as a Prognostic Index of Nutritional Status in Concurrent Cirrhosis and Hepatocellular Carcinoma, Journal of Clinical Gastroenterology, vol.47, issue.10, 2013.
DOI : 10.1097/MCG.0b013e318293a825

O. Mir, R. Coriat, B. Blanchet, J. Durand, P. Boudou-rouquette et al., Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma, PLoS ONE, vol.4, issue.5, p.37563, 2012.
DOI : 10.1371/journal.pone.0037563.t002

M. Nakano, M. Tanaka, R. Kuromatsu, H. Nagamatsu, K. Sakata et al., Efficacy, Safety, and Survival Factors for Sorafenib Treatment in Japanese Patients with Advanced Hepatocellular Carcinoma, Oncology, vol.15, issue.2, pp.108-114, 2013.
DOI : 10.1634/theoncologist.2009-0143

V. Ozenne, V. Paradis, S. Pernot, C. Castelnau, M. Vullierme et al., Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib, European Journal of Gastroenterology & Hepatology, vol.22, issue.9, pp.1106-1110, 2010.
DOI : 10.1097/MEG.0b013e3283386053